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ABSTRACT
Objectives: The aim of the study was to assess the usefulness of various tumor markers (CA125, HE4, bcl2) measured in 
serum, urine and saliva in the differential diagnosis of adnexal masses.
Material and methods: Our study was conducted at the Başkent University Medical School, Department of Obstetrics 
and Gynecology, Ankara, Turkey, between November 2010 and March 2011. Fifty patients with a suspicion of malignant 
adnexal mass and 30 controls were included in the study. Serum and urine CA-125, HE4, and bcl2 levels were evaluated 
for their role in the diagnosis of epithelial ovarian cancer (EOC).
Results: Serum CA-125 and HE4 levels, and urine HE4 levels were significantly higher in malignant cases as compared to 
controls (p < 0.05). Mean levels of bcl2 in saliva and urine were similar in malignant cases and controls (p > 0.05).
Conclusions: We demonstrated that serum CA125, serum HE4 and urine HE4 levels were elevated in patients with ovar-
ian cancer. These findings should be assessed in future studies with larger sample sizes in order to reach more definite 
conclusions.
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INTRODUCTION
Annually, 204.000 women are diagnosed with ovar-
ian cancer (OC), with 125.000 dying of the disease [1]. Ac-
cording to Globocan 2008, 1804 patients were diagnosed 
with ovarian cancer and 1204 died of the disease [2]. In the 
absence of effective screening methods, approximately 
70% of OC cases are diagnosed at advanced stages of the 
disease [3]. The 5-year overall survival following the diag-
nosis at an early stage is nearly 90%, which is in contrast 
with the 30% survival following diagnosis at an advanced 
stage [3]. In addition, the 5-year recurrence rate for patients 
diagnosed at advanced stages is about 80% [4]. These data 
underscore the importance of early diagnosis in this poten-
tially lethal disease. 
The established diagnostic utilities in ovarian cancer 
include pelvic examination, transvaginal ultrasound (TVUS), 
and serum tumor markers. With annual pelvic examina-
tions, early-stage OC is detected in 1/10.000 women [5]. 
Currently, CA125 remains to be the most commonly used 
tumor marker. CA125 is a glycoprotein marker which is el-
evated in 50% of early and 80–90% of advanced stages of the 
disease [6]. Moreover, CA125 levels may increase in benign 
gynecologic and non-gynecologic conditions as well. When 
used alone, OC may be detected in 1 out of 1000 screened 
subjects. Thus, the CA125 measurement alone is inadequate 
as a screening tool [5]. TVUS is considered to be the most 
effective imaging method to visualize the ovaries. The sen-
sitivity of this method for diagnosing ovarian malignancies 
has been estimated at 48–92% [7]. Various combinations of 
these diagnostic modalities have been tested to define the 
optimal method. 
Novel tumor markers are currently being investigat-
ed for the early diagnosis of OC. Among these, HE4 and 
bcl2 seem most promising. However, more data on the 
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effectiveness and feasibility of these markers are needed 
to incorporate them into routine clinical practice. Besides 
serum, body fluids which can be acquired in a non-invasive 
fashion, e.g. urine and saliva, are also being investigated for 
their potential to be tested for tumor markers [8–11]. Hu-
man epididymis protein-4 (HE4) and bcl2 (an anti-apoptotic 
marker) have been demonstrated to be elevated in urine of 
OC patients [8, 9]. Bcl2 is secreted into all body fluids and 
has been proposed as a novel tumor marker in early-stage 
OC [8, 12].
OBJECTIVES
In the present study, the utility of CA125, HE4 and 
bcl2 tumor markers was investigated for ovarian cancer 
diagnosis in patients with suspicious adnexal masses.
MATERIAL AND METHODS
This cross-sectional study was conducted at the Depart-
ment of Gynecologic Oncology, Başkent University Medical 
School, Ankara, Turkey. Local Ethics Committee approved of 
the study (KA10/62). Fifty patients, diagnosed with a suspi-
cious adnexal mass between October 2010 and March 2011, 
constituted the study group, and 30 healthy non-pregnant 
women who presented to our institution for a regular gy-
necologic examination comprised the control group.
Serum, urine, and saliva samples were preoperatively 
obtained from the study group, and at the time of the clini-
cal examinations after gathering the informed consent from 
the control group. Serum was tested for CA125 and HE4 lev-
els. Blood samples were centrifuged at 10800 rpm for 10 min, 
and the collected serum was stored at –80ºC. Urine samples 
were tested for HE4 and bcl2 levels. Urine samples were 
centrifuged at 3500 rpm for 15 min, and the supernatant 
fluid was stored at –80ºC. Saliva samples were obtained from 
all patients using Diametra Saliva Collection Device tubes 
and pipettes, and were kept at –20ºC for 24 hours. Next, the 
saliva samples were thawed, mixed, and homogenized us-
ing a vortex. The samples were centrifuged at 3500 rpm for 
15 min, and the supernatant fluid was again collected and 
frozen at –20ºC. This procedure was performed to increase 
the viscosity of the saliva samples. 
Serum and urine HE4 levels were measured using the 
enzyme immunometric assay (EIA) method (Fujirebio 
Diagnostics Inc., Sweden). This method is a solid phase 
non-competitive measurement, which is dependent on 
direct sandwich technique using 2H5 and 3D8 mono-
clonal antibodies directed against two epitopes on the 
HE4 C-WFDC chain. Picomolar (pM) units were utilized for 
HE4. Urine HE4 levels were assessed by measuring urine 
creatinine, and calculating a normalized HE4 (pM)/urine 
creatinine (mg/dL) ratio. 
The Risk of Malignancy Algorithm (ROMA) is a serum 
biomarker algorithm that aims to determine the risk of OC 
in women with an adnexal mass, and combines CA125, 
HE4, and the menopausal status. The formulas used in this 
calculation were as follows: 
(1) Premenopausal women 
Predictive index 
(PI) = –12.0 + 2.38*LN[HE4] + 0.0626*LN[CA125] 
(2) Postmenopausal women 
Predictive index 
(PI) = –8.09 + 1.04*LN[HE4] + 0.732*LN[CA125] 
Calculation of ROMA values
(3) ROMA value percentage% = exp(PI) / [1 + exp(PI)] × 100
Premenopausal > 12.5 postmenopausal > 14.4 high risk 
for epithelial ovarian cancer
Premenopausal < 12.5 postmenopausal < 14.4 low risk 
for epithelial ovarian cancer
Urine and saliva bcl2 levels (ng/mL) were assessed 
using the enzyme-linked immunosorbent assay — ELISA 
(Biovendor LM Inc; Czech Republic), with the sensitivity 
of < 0.5 ng/mL. Serum CA125 levels (U/mL) were meas-
ured using chemiluminescence microparticle immunoassay 
(CMIA) (Abbott Architect i2000; Abbott Laboratories; IL, 
USA). Patient charts were retrieved from the hospital com-
puter archives. Clinical data were evaluated, together with 
CA125, HE4, bcl2 and the final pathology reports.
Statistical analysis
Study data were analyzed with SPSS 17.0 computer 
software (Statistical Package for Social Sciences, SPSS Inc, 
Chicago, IL, USA). Categorical variables were expressed as 
count and percentage, whereas continuous variables were 
expressed as mean ± standard deviation (SD). Chi-square, 
Kruskal-Wallis and one-way ANOVA tests were used to com-
pare the study groups and subgroups, where appropriate. 
P-values of < 0.05 were considered as statistically significant. 
RESULTS
A total of 80 subjects were included in the study. Fifty pa-
tients with an adnexal mass comprised the study group, and 
30 healthy women were recruited as controls. Sociodemo-
graphic and clinical characteristics of the study population 
are presented in Table 1. Out of all patients with an adnexal 
mass, 32 were diagnosed with OC or borderline ovarian tu-
mor (BOT) on the final pathology examination, and 18 were 
found to have benign adnexal masses. Among the neoplas-
tic cases, 24 patients had OC, 7 had BOT, and 1 had a meta-
static gastric cancer (Krukenberg tumor). Twenty-three of 
the 24 OC subjects had epithelial ovarian cancer (EOC), 
and 1 had a sex cord-stromal tumor. Of the patients with 
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a benign ovarian pathology, 13 had an endometriotic cyst, 
1 dermoid cyst, 1 serous cystadenoma, 1 mucinous cystad-
enoma, and 1 torsioned ovarian cyst. Patients with OC were 
significantly older than patients with a benign ovarian pa-
thology (54.5 ± 15.34 vs. 32.39 ± 12.1 years, respectively) 
(p < 0.001). The postmenopausal status was more common 
in malignant cases. Fourteen (56.3%) of the malignant cases 
and 10 (33.3%) of the benign cases were postmenopausal. 
Of the 23 patients with EOC, 18 had stage III–IV (78.3%) 
disease at the time of diagnosis, whereas 5 (21.7%) patients 
had stage I disease. 
The study group (women with an adnexal mass) was 
further subdivided into two groups (malignant and benign). 
A total of 3 groups, including controls, were then com-
pared in terms of tumor marker levels (Table 2). Mean tu-
mor marker levels were also compared with regard to the 
menopausal status (Table 3). Patients with the final pathol-
ogy diagnosis of endometriosis and EOC were compared. 
In patients with endometriosis, mean serum CA125 was 
165.63 ± 192.91 U/mL, mean serum HE4 was 70.36 ± 43.32 pM, 
mean urine HE4 was 800.01 ± 256.38 pM. In patients with 
EOC, mean serum CA125 was 878.65 ± 1316.22 U/mL, 
serum HE4 was 270.64 ± 358.25 pM, and urine HE4 was 
954.50 ± 264.196 pM. Mean serum CA125 and serum 
HE4 levels were significantly higher in patients with EOC 
(p < 0.05). 
CA125 and serum HE4 levels were analyzed together 
according to the ROMA scoring system. Out of the 31 pre-
menopausal patients, 19 (61.3%) were classified as having 
low risk, whereas 12 (38.7%) were grouped as high-risk. 
Seven patients (36.8%) in the postmenopausal group were 
low-risk, and 12 (63.2%) were high-risk, according to ROMA. 
The sensitivity, specificity, positive predictive values (PPV), 
and negative predictive values (NPV) for the ROMA score 
to detect malignancy in postmenopausal patients were 
66.7%, 38.5%, 50%, and 55.6%, respectively. In premenopau-
sal patients with ovarian malignancy, however, sensitivity, 
specificity, PPV and NPV values were 41.7%, 52.6%, 35.7%, 
and 58.8%, respectively.
Table 1. Sociodemographic and clinical characteristics of the study 
population
Study group (n: 50) Control group (n: 30)
Age 46.54 ± 17.75(min 19–max 84)
40.5 ± 14.44
(min 23–max 73)
Gravidity 1.76 ± 1.74 1.13 ± 0.97
Parity 1.62 ± 1.61 1.03 ± 0.92
Premenopausal 31 (62%) 20 (66.6%)
Postmenopausal 19 (38%) 10 (33.3%)
CA125 (U/mL) 461.08 ± 970.31 16.08 ± 6.86
Table 2. Comparison of tumor marker levels between women with malignant adnexal masses, benign adnexal masses, and controls
Group
CA125
Median (min–max)
Mean ± SD
Serum HE4
Median (min–max)
Mean ± SD
Urine HE4
Median (min–max)
Mean ± SD
Urine Bcl2
Median (min–max)
Mean ± SD
Saliva bcl2
Median (min–max)
Mean ± SD
Malignant 105.5 (7.3–4791)645.18 ± 1172
61.6 (7.6–1362)
202.11 ± 321
1010 (24.95–1247)
968.35 ± 229.68
1.43 (0.5–1.86)
1.32 ± 0.30
1.52 (1.06–12.4)
2.64 ± 2.59
Benign 87 (6.3–772)133.79 ± 172.02
59.38 (4.5–152.5)
66.96 ± 41.46
858.5 (327–1215)
811.72 ± 265.88
1.44 (0.5–1.52)
1.34 ± 0.25
1.7 (1.50–10.52)
2.39 ± 2.13
Controls 15.9 (6.8–38)16.06 ± 6.86
84 (5.6–254)
87.29 ± 68.43
799.50 (295–1313)
804.59 ± 259.99
1.49 (1.18–1.68)
1.47 ± 0.12
1.64 (1–12.4)
2.62 ± 2.21
P 0.004 0.041 0.022 0.044 0.928
Table 3. Comparison of tumor marker levels according to the menopausal status
Menopausal status CA125 Serum HE4 Urine HE4
Premenopausal
Malignant 203.77 ± 297.39 144.26 ± 353.39 975.49 ± 171.86
Benign 140.02 ± 175.20 64.40 ± 41.25 788.88 ± 255.21
Controls 17.45 ± 7.29 88.81 ± 62.36 827.38 ± 260.90
p 0.016 0.5 0.078
Postmenopausal
Malignant 988.49 ± 1467.67 247.11 ± 297 962.79 ± 271.18
Benign 27.9 110.50 1200
Controls 13.36 ± 5.20 84.25 ± 82.83 779 ± 270.21
p 0.088 0.249 0.145
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DISCUSSION
Epithelial ovarian cancer (EOC) is the most lethal ma-
lignancy of the female genital tract. Its indolent clinical 
course, together with the absence of early symptoms, are 
the reasons why patients are diagnosed in advanced stages, 
with the 5-year survival of nearly 30% [13]. Numerous studies 
have evaluated alternative markers for diagnosing EOC at 
early stages (stage I–II), in order to increase life expectancy. 
Our study included 50 patients with an adnexal mass, and 
30 controls. Serum CA125 and HE4, urine HE4 and bcl2, 
and saliva bcl2 levels were evaluated in these patients, and 
the diagnostic values of these markers were investigated. 
CA125 is the single most commonly used serum marker 
in EOC [14]. Following the discovery of this antigen, vari-
ous authors investigated and confirmed its diagnostic and 
prognostic role in EOC. Unfortunately, CA125 is elevated 
in only about 50% of patients with early-stage EOC [6, 15]. 
CA125 is a much more sensitive and specific assay when 
used in postmenopausal women, as benign pathologies in 
premenopausal women limit is diagnostic accuracy in that 
group [16]. A number of previously conducted studies have 
shown that the measurement of serum CA125 alone is not 
adequate in the screening and diagnosis of EOC. Regardless, 
it is effective in the follow-up of patients with pre-treatment 
elevated values [17, 18]. Therefore, alternative methods for 
the evaluation of suspicious adnexal masses have been 
proposed [19]. With the introduction of monoclonal anti-
body-dependent assays, Human epididymis protein-4 (HE4) 
has emerged as a sensitive and specific tumor marker, with 
promising results in EOC [20, 21]. It is synthesized in the 
endoplasmic reticulum and perinuclear Golgi apparatus 
within the cancer cells. Previous studies have shown that 
32% of EOC patients had elevated HE4 levels in serum [22]. 
Its sensitivity is comparable to that of CA125, however it has 
higher specificity for EOC [21]. In a study by Havrileski et al., 
it was demonstrated that a combined use of HE4 with other 
tumor markers was effective in the early diagnosis of EOC 
both, in the primary and recurrent disease settings [23, 24]. 
Moore et al., evaluated CA125, SMRP, HE4, CA72-4, activin, 
inhibin, osteopontin, epidermal growth factor receptor and 
found that the combination of CA125 and HE4 had a sensi-
tivity of 76% and a specificity of 95% in differential diagnosis 
between benign and malignant adnexal masses [25, 26]. 
In our study, three tumor markers (CA125, HE4 and bcl2) 
were evaluated in sera, saliva and urine. Serum CA125, se-
rum HE4 and urine HE4 levels were significantly higher 
in patients with ovarian malignancy. Interestingly, urine 
bcl2 levels were significantly higher in patients without 
OC. Moreover, saliva bcl2 levels were similar in benign and 
malignant cases (p > 0.05). 
In a study by Huhtinen et al., 129 patients with endome-
triosis were compared in terms of HE4 with 14 EOC, 16 en-
dometrial cancer, and 66 control patients [27]. Mean serum 
HE4 in patients with EOC was 268.3 ± 2670 pM, whereas it 
was 43.5 ± 13.4 pM in patients with endometriosis. Although 
mean serum HE4 levels were higher in our study, we also 
observed similar results. It was concluded that in benign 
cases, HE4 was as high as in patients with EOC. 
The ROMA scores (Risk of Ovarian Malignancy Algo-
rithm) were assessed for our study groups [25]. We found 
that ROMA was most sensitive for postmenopausal patients 
with ovarian malignancy. In a study by Montagnana et al., 
55 patients with EOC were compared with 49 patients with 
an adnexal mass and 49 healthy women. Serum CA125, 
serum HE4 and ROMA scores were evaluated [28]. It was 
demonstrated that ROMA was useful primarily in post-
menopausal women, with very little additional effective-
ness in premenopausal patients. HE4 may be used solely in 
premenopausal patients. Jacobs et al., concluded that the 
concomitant use of CA125 and HE4 was not a very effective 
strategy in clinical practice [29]. Our findings also confirmed 
these results. 
Urine tumor markers have been previously assessed in 
a number of studies, with the assumption that low molecular 
weight (< 50 kd) markers could be filtrated from the glo-
merula and be detected prior to the elevation in serum. In 
a study by Anderson et al., bcl2, which is an anti-apoptotic 
protein, was assessed in the urine of patients with EOC, 
benign adnexal masses, and healthy controls. It was shown 
that urine bcl2 was elevated in patients with EOC, and was 
a useful and non-invasive marker by itself or in combination 
with other tumor markers [8]. On the contrary, in our study 
we found that urine bcl2 was higher in the control group. 
This finding may be due to a relatively small sample size, 
and should be further evaluated. Urine HE4 levels were also 
evaluated in our study. We found that urine HE4 was signifi-
cantly higher in patients with OC. In a study by Hellstrom et 
al., 79 patients with EOC (15 early and 64 advanced stage), 
20 patients with benign adnexal masses, and 36 healthy 
subjects were compared in terms of urine HE4. They found 
the sensitivity of urine HE4 in early EOC to be 86.6%, and 
90.5% in advanced EOC [9]. The sensitivity for detecting 
EOC was similar for serum and urine HE4. In our study, we 
also found that serum HE4 levels were significantly higher 
in malignant cases. 
Saliva of the patients has also been previously assessed 
in the diagnosis of OC. A number of immunologic, metabolic, 
gastrointestinal and vitamin synthesis disorders, paren-
chymal and secretory alterations occur within the salivary 
glands. As saliva is easy to obtain, with minimal risk of infec-
tious disease spread, it is preferred in the diagnosis of several 
diseases. In a previous study, although serum CA125 was 
found to be significantly higher in sera of patients with 
ovarian cancer, there were no differences in terms of saliva 
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CA125 levels between EOC and controls [10]. In our study, 
we only assessed the bcl2 levels in the saliva of the study 
subjects but we did not detect significant differences in 
malignant, benign, and control subjects. 
Currently, the available markers which are measured in 
various body fluids are not adequately accurate in the preop-
erative differential diagnosis of adnexal masses [30]. Pelvic 
exam, serum CA125 transvaginal ultrasound, or a combina-
tion of these modalities are frequently used. However, none 
of these methods are definitive, and demand further surgi-
cal evaluation in high-risk patients. It is critical for high-risk 
patients to be operated in comprehensive oncology centers, 
preferably by gynecologic oncologists, as the survival rate is 
higher in these appropriately managed women [31]. 
CONCLUSIONS
Our study detected elevated serum CA125, serum 
HE4 and urine HE4 levels in patients with ovarian cancer. 
Also, ROMA was found to be a sensitive method of detect-
ing postmenopausal malignant adnexal masses. On the 
other hand, the diagnostic significance of saliva and urine 
bcl2 concentrations was not confirmed. These findings 
should be assessed in future studies with larger sample 
sizes in order to reach more definite conclusions. 
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